Should we fear tubing adsorption of antibacterial drugs in extracorporeal membrane oxygenation? An answer for cephalosporins and carbapenems
Extracorporeal membrane oxygenation (ECMO) is a supportive care used in the management of patients with life-threatening cardiac and/or respiratory failure. The use of ECMO in the management of cardiopulmonary disease is increasing. Since its first application in the 70's, performances of the technology and devices have been dramatically improved, leading to safer and more effective system (1). Hence, indications of ECMO have expanded, and are also becoming better defined, although data from clinical trials are needed in order to build thorough practice guidelines (1, 2) . In addition to clinical aspects, potential impact of ECMO on the pharmacokinetics (PK) of drugs used in these patients must be considered to improve the therapeutic strategy. The alterations in PK parameters described in the critically ill population eligible for ECMO therapy may induce additional PK variability (3) . Although clinical data are sparse, recent studies suggested that ECMO circuit itself is responsible for PK alterations which could increase the risk of therapeutic failure or toxicity (3) (4) (5) (6) (7) . Sequestration of drugs in ECMO circuits has been proposed as an explanation for the low concentrations observed in clinical practice (4, 8) . Thus, studies on the impact of ECMO devices on drug PK are warranted to
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optimize dosage and ensure treatment efficacy. During antibacterial treatment, the early achievement of drugs concentrations within the therapeutic target is associated with improved outcome. More specifically, for betalactam agents, maintaining drug concentrations above the minimal inhibitory concentration of the drug on the bacteria targeted is crucial to ensure treatment success (9) . Among the factors potentially associated with subtherapeutic levels of betalactam agents, ECMO is a major cause of concern, as this intervention applies to the sickest patients, for whom sub-optimal use of drugs will be life-threatening (10).
We aimed to characterize the behavior of antibiotics (ATB) commonly used in these patients Cephalosporin concentrations were measured using high performance liquid chromatography (HPLC) associated with UV-spectrometry detection and according to the validated method reported by Verdier et al. (11) . The method used to quantify carbapenems was adapted from (12) . Briefly, analytes were extracted from plasma using protein precipitation with acetonitrile followed by a liquid-liquid extraction with dichloromethane. Extracts were analyzed by HPLC tandem mass spectrometry.
Changes in mean remaining drug concentrations over time were compared between control and experimental conditions by modeling using a linear mixed effect model as previously done in some similar studies (5, 13) . The mixed effect model was then fitted with R software version 3.0.2 and the "nlme" library (14) .
No significant differences in remaining concentrations in tubing or controls were observed for CS and CP. This suggests that CS and CP are not sequestrated by ECMO tubing (Figure 1 ). After 4 hours of incubation at 37°C, the decrease in drug concentrations was significant (> 15%) for imipenem, cefepime and cefotaxime, but with the same extent in the controls and the experimental conditions, and thus can be ascribed to sub-optimal drug stability of most betalactam agents.
These results show that PK changes in ECMO patients treated with CS or CP might not be due to tubing sequestration. It was suspected, on the ground that betalactam are hydrophilic drugs. Indeed,
Wildschut et al., reported a correlation between octanol/water partition coefficient (log P) of a drug
and its clearance during ex-vivo procedure conducted with neonatal circuits. These authors have
showed that drug loss in ECMO circuit is lower for hydrophilic drugs such as betalactam (7). A lack of effect of ECMO on the PK of hydrophilic drugs has also been highlighted in patients, particularly with the antiviral oseltamivir (6). On the opposite, Shekar et al. have reported a substantially higher clearance of meropenem, a CP drug, during ex-vivo experiments and in adult patients treated with ECMO (4, 10) . In a larger case-control study, no difference was found in meropenem PK between ECMO patients and non-ECMO patients (15) . In view of these conflicting results, experimental study like the present one appears useful to understand underlying mechanisms which make ECMO device a factor of PK modifications. Thus, PK alterations of hydrophilic drugs might be more likely due to hemodilution mechanism associated with the additional compartment represented by the circuit or high volume of fluid supplementation requested in intensive care patients. Nevertheless, log P value of a drug is not the only parameter determining the drug disposition in an ECMO circuit. Shekar et al.
have demonstrated in an ex-vivo study that as lipophilicity, degree of protein binding may be involved as well (13) . In the present work we did not observed any influence of this factor since drugs studied have disparate levels of protein binding (respectively 70%, 2%, 95%, 30%, 90%, 10%, 19% for imipenem, meropenem, ertapenem, cefotaxime, ceftriaxone, ceftazidime, cefepime) but the same profile of drug recovery in the circuit compared to the control group (no significant difference).
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